Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2026)

Neurocrine Biosciences (NBIX) has reported Gross Margin for 10 consecutive years, with 97.58% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 92.0% year-over-year to 97.58%; the trailing twelve-month figure through Jun 2026 stood at 97.97% (down 57.0% YoY), and the FY2025 full-year result was 98.18%, down 38.0% from the prior year.
• Gross Margin slipped to 97.58% in Q2 2026 per NBIX's latest filing, from 98.31% in the prior quarter.
• Across five years, Gross Margin topped out at 98.73% in Q2 2022 and bottomed at 97.46% in Q2 2023.
• Historically, Gross Margin has averaged 98.24% across 5 years, with a median of 98.37% in 2025.
• The sharpest annual moves came in 2023 and 2024: Gross Margin sank 127 bps in 2023, then jumped 98 bps in 2024.
• Over 5 years, Gross Margin stood at 98.13% in 2022, then grew by 0 bps to 98.35% in 2023, then climbed by 0 bps to 98.52% in 2024, then retreated by 1 bps to 97.82% in 2025, then dropped by 0 bps to 97.58% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 97.58%, 98.31%, and 97.82% for Q2 2026, Q1 2026, and Q4 2025 respectively.